

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement accompanies the new patent application submitted herewith of the following Inventors: Gregg Brian FEIGELSON; Joseph ZELDIS; Ivo Ladislav JIRKOVSKY

For: Process for Synthesizing N-Aryl Piperazines with Chiral N'-1-[Benzoyl(2-Pyridyl)Amino]-2-Propane Substitution.

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

2. ☒ Previously Cited Information

No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120. Prior application is Application Number 10/384,845 filed on March 12, 2003 for Process for Synthesizing N-Aryl Piperazines with Chiral N'-1-[Benzoyl(2-Pyridyl)Amino]-2-Propane Substitution.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EU947814206US addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

2-18-04
Date

John R. Barker
John R. Barker

3. ☐ Newly Cited Information
A legible copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed, except that no copy of a pending U.S. application, a U.S. patent, or a U.S. patent application publication is enclosed.
4. ☐ Concise Explanation
Documents cited above which are not in the English Language
a. ☐ have been explained in the specification.
b. ☐ have an abstract (or other concise explanation) in English enclosed or, if readily available, a translation into English of the document is enclosed.
5. Form PTO-1449 is enclosed in duplicate.
6. Customer Number 25291.



Arnold S. Milowsky
February 18, 2004
Attorney for Applicants
Reg. No. 35,288

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (484) 865-8607

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application Number		Not yet assigned
				Filing Date		February 18, 2004
				First Named Inventor		Gregg B. Feigelson
				Group Art Unit		1624
				Examiner Name		E. Bernhardt
Sheet	1	of	1	Attorney Docket Number		AM100723 P1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.	5,424,313		Jan Hertog et al.	06-13-1995	
	2.	6,127,357		Ian A. Cliffe et al.	10-03-2000	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	3.	WO	94/24115		Yoichi Kawashima et al.	10-27-1994		<input type="checkbox"/>
	4.	WO	95/33725		Christopher Brightwell et al.	12-14-1995		<input type="checkbox"/>
	5.	WO	95/33743		Christopher Brightwell et al.	12-14-1995		<input type="checkbox"/>
	6.	WO	96/01656		Ian A. Cliffe et al.	01-25-1996		
	7.	WO	97/03982		Andrew Fensome et al.	02-06-1997		<input type="checkbox"/>
	8.	WO	97/37655		Mark E. Duggan et al.	10-16-1997		<input type="checkbox"/>
	9.	WO	02/44142		Wayne E. Childers et al.	06-06-2002		
	10.	JP	01125357	A2	Tadahiro Sawayama et al.	05-17-1989		<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS					T
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	11.	Natsuka KAGAYAKI et al., J. Med. Chem., 1987, 1779-1787, 30			<input type="checkbox"/>
	12.	Frank KERRIGAN et al., Tetrahedron Letters, 1998, 2219-2222, 39			<input type="checkbox"/>
	13.	Sheryl J. HAYS, J. Labelled Compounds and Radiopharmaceuticals, 1986, 351, 24(4)			<input type="checkbox"/>
	14.	Jean-Louis PEGLION et al., J. Med. Chem., 1995, 4044-4055, 38			<input type="checkbox"/>
	15.	Shawn J. STACHEL et al., Tetrahedron Letters, 1999, 5811-5812, 40			<input type="checkbox"/>
	16.	Julian M.C. GOLEC et al., Bioorganic & Medicinal Chemistry Letters, 1997, 2181-2186, 7(17)			<input type="checkbox"/>
	17.	Dan MULLER, J. Org. Chem., 1997, 411-416, 62			<input type="checkbox"/>
	18.	G. Mark TAYLOR et al., Tetrahedron Letters, 1996, 1297-1300, 37(8)			<input type="checkbox"/>
	19.	Database Crossfire Beilstein, Reg. No. 3915193			<input type="checkbox"/>
	20.	Database Crossfire Beilstein, Reg. No. 1512459			<input type="checkbox"/>
	21.	Zoltan ZUBOVICS, Eur. J. Med. Chem., 1986, 370-378, 21(5)			<input type="checkbox"/>
	22.	G. CIGNARELLA et al., Il Farmaco - Ed. Sc., 1976, p. 194, 196, v. 31			<input type="checkbox"/>
	23.	Lee T. BOULTON, J. Chem. Soc., Perkin Trans. 1, 1999, 1421-1429			<input type="checkbox"/>
	24.	G. CIGNARELLA, Il Farmaco - Ed. Sc., 1976, 194-200, 31(3)			<input type="checkbox"/>
	25.	Ulrike BURKARD et al., Chem. Ber., 1986, 1594-1612, 119			<input type="checkbox"/>
	26.	Wincenty KWAPISZEWSKI et al., Acat Pol. Pharm., 1999, 41-47, 56(1) (Abstract)			<input type="checkbox"/>
	27.	Michimasa IZUMI et al., Chem. and Pharm. Bull. (Japan), 1954, 275-279, 2(3)			<input type="checkbox"/>
	28.	Isao AIKO et al., Chem. and Pharm. Bull. (Japan), 1957, 487-488, 5(5)			<input type="checkbox"/>
	29.	Syed M. QUADRI et al., Bioorganic & Medicinal Chemistry Letters, 1992, 1661-1664, 2(12)			<input type="checkbox"/>
	30.	G. Mark TAYLOR et al., Tetrahedron Letters, 1996, 1297-1300, 37(8)			<input type="checkbox"/>
	31.	Robert V. HOFFMAN et al., Tetrahedron Letters, 1990, 2953-2956, 31(21)			<input type="checkbox"/>
	32.	Sandrine MARCHAIS et al., Bioorganic & Medicinal Chemistry, 2001, 695-702, 9			<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.